… Our search aimed to find articles containing data on immunogenicity, vaccine efficacy,
vaccine effectiveness, and duration of immunity and safety of MCV1 administered to infants …

… vaccine (PCV) in infants <2 years of age. Low birth weight (LBW; ≤2500 g) and preterm (PT;
≤38 weeks) infants … the safety, immunogenicity and efficacy of PCV in these infants based …

… Overall, 26 of 27 primary immunogenicity end points in this study were met. The failure to
meet noninferiority criteria for FHA GMC after the infant series, while meeting criteria for …

… US study that compares the safety, tolerability, and immunogenicity of PCV13 with that of …
routine pediatric vaccinations, according to the US-recommended infant vaccination schedule. …

… vaccine to the schedule more acceptable. This report describes the immunogenicity and
safety of a … candidate vaccine (Pnc9-MenC) given to UK infants at ages 2, 3, and 4 months. …

… We aimed to summarise the RSV vaccine immunogenicity based on each paper's definition
of “immune-response” (described in the relevant journal papers); commonly, for instance, a …

… We examined the immunogenicity of routine vaccines in subsets of infants (n=245 with
4CMenB, n=252 with routine vaccines alone). Responses to all constituent antigens reached …

… safety and immunogenicity of three age-appropriate PCV-13 catch-up vaccination schedules
in older infants and children naive to previous pneumococcal vaccination Citation[58]. PCV-…

… This study evaluated the immunogenicity and safety of a licensed meningococcal serogroup
B vaccine (4CMenB) administered alone according to reduced schedules in infants or catch-…

… stocks of prepandemic vaccines on hand. This study evaluated the immunogenicity, safety,
and tolerability of 2 doses of a MF59-adjuvanted, prepandemic, H5N1 vaccine, administered …